A new claim from scientists has forced us to reconsider what we once knew about ourselves, thus creating huge potential if we can understand our hidden half.
Direct to consumer testing can potentially be quite dangerous without appropriate regulations and support to fully understand the implications of the information a consumer receives.
A drug combination has been discovered that could potentially reverse disease symptoms by adjusting natural cellular functions.
23andMe CEO and co-founder Anne Wojcicki says consumers don’t need experts to interpret results from genetic risk tests, and compared the information her company offers to at-home pregnancy tests. But is it that simple?
Researchers have used CRISPR to develop a pig model of Huntington’s disease that better mimics how the disease progresses in humans.
Concerningly, 20% of publicly funded cancer clinical trials in the United States fail because investigators are unable to enroll enough participants.
Singlera Genomics, a non-invasive genetic diagnostics company that focuses on early-stage cancer detection, has secured a $60 million Series A+ financing.
With the demand for direct-to-consumer genetic tests on the rise, a new analysis has questioned how reliable the results really are.
Healthcare tech startup Theranos was riding high back in 2014. But when a reporter raised questions, its media reps circled the wagons.
Home genetic tests like AncestryDNA and 23andMe are more popular than ever. But having widespread access to personal genetic information—without the knowledge of how to interpret results—can lead to problems.
New study brings new insights into the correlation of physical activity and dietary habits with weight gain in people who carry different variations of the FTO gene—aka ‘the fat gene.’
23andMe has received the first-ever FDA authorisation for a direct-to-consumer genetic test for cancer risk for its BRCA1 and BRCA2 report.